» Articles » PMID: 10085631

Economic Burden of Blindness in India

Overview
Specialty Ophthalmology
Date 1999 Mar 23
PMID 10085631
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Economic analysis is one way to determine the allocation of scarce resources for health-care programs. The initial step in this process is to estimate in economic terms the burden of diseases and the benefit from interventions for prevention and treatment of these diseases. In this paper, the direct and indirect economic loss due to blindness in India is calculated on the basis of certain assumptions. The cost of treating cataract blindness in India is estimated at current prices. The economic burden of blindness in India for the year 1997 based on our assumptions is Rs. 159 billion (US$ 4.4 billion), and the cumulative loss over lifetime of the blind is Rs. 2,787 billion (US$ 77.4 billion). Childhood blindness accounts for 28.7% of this lifetime loss. The cost of treating all cases of cataract blindness in India is Rs. 5.3 billion (US$ 0.15 billion). Similar estimates for causes of blindness other than cataract have to be made in order to develop a comprehensive approach to deal with blindness in India.

Citing Articles

Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review.

Teoh L, Kellett S, Patel D, Cortina-Borja M, Solebo A, Rahi J Pharmacoeconomics. 2023; 42(3):275-299.

PMID: 37971639 PMC: 7615631. DOI: 10.1007/s40273-023-01311-5.


Estimating the costs of blindness and moderate to severe visual impairment among people with diabetes in India.

Redding S, Anderson R, Raman R, Sivaprasad S, Wittenberg R BMJ Open. 2023; 13(6):e063390.

PMID: 37355259 PMC: 10314483. DOI: 10.1136/bmjopen-2022-063390.


The economic and social costs of visual impairment and blindness in India.

Wong B, Singh K, Khanna R, Ravilla T, Shalinder S, Sil A Indian J Ophthalmol. 2022; 70(10):3470-3475.

PMID: 36190029 PMC: 9789807. DOI: 10.4103/ijo.IJO_502_22.


Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.

Bhadhuri A, Droschel D, Guldimann M, Jetschgo C, Banhazi J, Schwenkglenks M BMC Health Serv Res. 2022; 22(1):837.

PMID: 35765055 PMC: 9241179. DOI: 10.1186/s12913-022-08211-y.


Current estimates of the economic burden of blindness and visual impairment in India: A cost of illness study.

Mannava S, Borah R, Shamanna B Indian J Ophthalmol. 2022; 70(6):2141-2145.

PMID: 35648000 PMC: 9359234. DOI: 10.4103/ijo.IJO_2804_21.